Alesta Therapeutics Raises €65 Million Series A Financing to Advance Oral Small Molecules for Rare Diseases

Alesta Therapeutics, a biotechnology company focused on developing transformative small molecule therapies for rare diseases, today announced the closing of an oversubscribed €65 million Series A financing round. The round was co-led by Frazier Life Sciences and Droia Ventures, with participation from Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital and SSI Strategy.